ProCE Banner Activity

RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Multimedia
Watch this on-demand Webcast capturing a live CCO Webinar to learn more about the latest data on RET inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with RET-altered NSCLC or thyroid cancer.

Released: February 12, 2021

Expiration: February 11, 2022

No longer available for credit.

Share

Faculty

Taofeek K. Owonikoko

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Learning Objectives

  • Evaluate the clinical utility of RET as a predictive biomarker for targeted therapy in NSCLC and thyroid cancer
  • Apply current recommendations to identify patients who should receive testing, provide effective counseling, and tailor biomarker testing options to the individual patient’s needs
  • Summarize ongoing research regarding the utility of selective RET inhibitors in patients with RET fusion–positive NSCLC, RET-mutant MTC, and RET fusion–positive thyroid cancer
  • Compare and contrast the different methodologies and assays for identifying RET alterations
  • Identify patients with RET-altered tumors who are candidates for ongoing clinical trials
  • Develop a proactive management plan for adverse events associated with therapies used to treat RET fusion–positive NSCLC, RET-mutant MTC, and RET fusion–positive thyroid cancer

Faculty Disclosure

Primary Author

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Taofeek K. Owonikoko, MD, PhD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aeglea, Amgen, Astellas, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Celgene, Corvus, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, Stemcentrx, and United Therapeutics; has received consulting fees from AbbVie, Amgen, Armo, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron, Lilly, MedImmune, Merck, Novartis, PharmaMar, Sandoz, Seattle Genetics, Takeda, and Xcovery; has received fees for non-CME/CE services from EMD Serono and Roche/Genentech; and has ownership interests in Cambium.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Sara Fagerlie, PhD

Sara Fagerlie, PhD, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.